{"filing":{"accession_number":"0001213900-26-071721","cik":"0001821586","ticker":"MLTX","company_name":"MoonLake Immunotherapeutics","form":"8-K","filing_date":"2026-06-25","report_date":null,"primary_document":"ea0295766-8k_moonlake.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1821586/000121390026071721/ea0295766-8k_moonlake.htm"},"events":[{"id":13671,"run_id":12141,"accession_number":"0001213900-26-071721","anchor_item_number":"1.01","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"MoonLake entered into an underwriting agreement on June 23, 2026 to conduct a public offering of 9,000,000 Class A ordinary shares at $20.00 per share, plus pre-funded warrants and an option for underwriters to purchase an additional 1,500,000 shares. The offering is expected to generate approximately $200 million in gross proceeds. This is a material dilutive equity issuance that would significantly affect shareholder ownership percentages and is disclosed under Item 1.01 as a material definitive agreement.","company_name":"MoonLake Immunotherapeutics","ticker":"MLTX","filing_date":"2026-06-25","form":"8-K","submitted_at":null,"items":[{"id":10881,"accession_number":"0001213900-26-071721","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"MoonLake entered into an underwriting agreement on June 23, 2026 to conduct a public offering of 9,000,000 Class A ordinary shares at $20.00 per share, plus pre-funded warrants and an option for underwriters to purchase an additional 1,500,000 shares. The offering is expected to generate approximately $200 million in gross proceeds. This is a material dilutive equity issuance that would significantly affect shareholder ownership percentages and is disclosed under Item 1.01 as a material definitive agreement.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-25T10:19:36.590040+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":10881,"accession_number":"0001213900-26-071721","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"MoonLake entered into an underwriting agreement on June 23, 2026 to conduct a public offering of 9,000,000 Class A ordinary shares at $20.00 per share, plus pre-funded warrants and an option for underwriters to purchase an additional 1,500,000 shares. The offering is expected to generate approximately $200 million in gross proceeds. This is a material dilutive equity issuance that would significantly affect shareholder ownership percentages and is disclosed under Item 1.01 as a material definitive agreement.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-25T10:19:36.590040+00:00","company_name":"MoonLake Immunotherapeutics","ticker":"MLTX","filing_date":"2026-06-25"}]}